Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
This study has been completed.
Sponsor:
Talon Therapeutics, Inc
Information provided by (Responsible Party):
Talon Therapeutics, Inc
ClinicalTrials.gov Identifier:
NCT00144963
First received: September 1, 2005
Last updated: May 11, 2012
Last verified: December 2011
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to find the highest safe dose and to assess the anti-tumor effect of liposomal vincristine with dexamethasone in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
| Condition | Intervention | Phase |
|---|---|---|
|
Acute Lymphoblastic Leukemia |
Drug: Vincristine Sulfate Liposomes Injection Drug: Dexamethasone |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase I-II Study of Liposomal Vincristine (VSLI) and Dexamethasone in Relapsed or Refractory Acute Lymphoblastic Leukemia |
Resource links provided by NLM:
Drug Information available for:
Dexamethasone
Dexamethasone acetate
Vincristine sulfate
Dexamethasone sodium phosphate
Sulfate ion
U.S. FDA Resources
Further study details as provided by Talon Therapeutics, Inc:
Primary Outcome Measures:
- MTD of VSLI [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]Subjects had to receive at least 1 course consisting of 4 weekly infusions of VSLI at the assigned drug dose with a minimum 2 weeks of observation after the last VSLI dose to be included in the evaluation of the MTD.
| Enrollment: | 36 |
| Study Start Date: | July 2002 |
| Study Completion Date: | August 2006 |
| Primary Completion Date: | August 2006 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: VSLI
Vincristine Sulfate Liposomes Injection (VSLI)
|
Drug: Vincristine Sulfate Liposomes Injection
Study treatment consists of infusion of VSLI intravenously over 60 minutes on Day 1 and Days 8, 15 and 22 (+/- 2 days).
Other Name: Marqibo
Drug: Dexamethasone
Study treatment consists of 40 mg dexamethasone, daily orally or intravenously, on Days 1-4 (+/- 2 days) and Days 11-14 (+/- 2 days).
|
Detailed Description:
OBJECTIVES:
- Determine the maximum tolerated dose (MTD) of liposomal vincristine given with dexamethasone in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
- Determine the efficacy of liposomal vincristine given with dexamethasone in these patients.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Previously treated, relapsed or refractory ALL (including lymphoblastic lymphoma and Burkitt's subtypes) with measurable disease.
- Performance status ≤3 (ECOG).
- All ages are eligible. Those aged 12 years or older may be counted towards the MTD in the Phase I portion of the trial. Pediatric patients are eligible, but must be treated at a dose level previously tested in an adult (one full course).
- Adequate liver function (bilirubin ≤2 x upper limit normal), and renal function (creatinine ≤2 x upper limit normal).
- Negative pregnancy test in females of childbearing potential.
- Patients with prior history of stem cell transplant are eligible if they meet all other eligibility requirements.
Exclusion Criteria:
- Active serious infection not controlled by oral or intravenous antibiotics.
- Treatment with any investigational agents or chemotherapy agents in the last 21 days before study entry, unless full recovery from side effects has occurred or the patient has rapidly progressive disease judged to be life threatening by the Investigator.
- Concurrent treatment with other anti-cancer agents other than dexamethasone.
- Known CNS leukemia or lymphoma requiring intrathecal or craniospinal radiation therapy or with CNS neuropathy limiting evaluation of study drug. Patients with controlled CNS disease (no progression signs or symptoms at the time of study entry) may be eligible after approval by the Principal Investigator. Lumbar puncture not required in asymptomatic patients.
- Prior history of Grade 3 or 4 sensory or motor neuropathy related to chemotherapeutic treatment, or persistent Grade 2 or greater active neuropathy.
- History of active neurologic disorders unrelated to chemotherapy (including familial neurologic diseases and acquired demyelinating disorders).
- Prior history of hypersensitivity reactions to vincristine or any of the other components of VSLI.
- Pregnant and/or lactating women; or fertile men or women not willing to use contraception.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00144963
Locations
| United States, Georgia | |
| Emory University | |
| Atlanta, Georgia, United States, 30322 | |
| United States, Illinois | |
| University of Chicago Medical Center | |
| Chicago, Illinois, United States, 60637 | |
| United States, Texas | |
| University of Texas M.D. Anderson Cancer Center | |
| Houston, Texas, United States, 77030 | |
Sponsors and Collaborators
Talon Therapeutics, Inc
Investigators
| Principal Investigator: | Deborah Thomas, MD | MD Anderson Cancer Center, Department of Hematology/Oncology |
| Principal Investigator: | Wendy Stock, MD | University of Chicago |
| Principal Investigator: | Leonard Heffner, MD | Emory University |
More Information
Additional Information:
No publications provided
| Responsible Party: | Talon Therapeutics, Inc |
| ClinicalTrials.gov Identifier: | NCT00144963 History of Changes |
| Other Study ID Numbers: | VSLI-06-ALL |
| Study First Received: | September 1, 2005 |
| Results First Received: | May 11, 2012 |
| Last Updated: | May 11, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Leukemia Leukemia, Lymphoid Precursor Cell Lymphoblastic Leukemia-Lymphoma Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Dexamethasone acetate Dexamethasone Dexamethasone 21-phosphate Vincristine BB 1101 Anti-Inflammatory Agents |
Therapeutic Uses Pharmacologic Actions Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Central Nervous System Agents Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Protease Inhibitors Enzyme Inhibitors |
ClinicalTrials.gov processed this record on May 21, 2013